PerkinElmer to Acquire BioLegend in $5.25-Billion Deal
PerkinElmer has entered into an agreement to acquire BioLegend, a global developer and manufacturer, in a deal valued at $5.25 billion.
PerkinElmer has entered into an agreement on July 26, 2021 to acquire BioLegend, a global developer and manufacturer of antibodies and reagents used in biomedical research (cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing). The transaction is expected to close by the end of 2021 and is valued at $5.25 billion.
With this acquisition, PerkinElmer will offer solutions in areas such as cell and gene therapy discovery. The company will also move into new spaces like proteogenomics. BioLegend’s new headquarters in San Diego, Calif. will serve as PerkinElmer’s center for research reagent content development.
Source: PerkinElmer
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
